Skip to main content

Table 2 Study characteristics in Multibacillary Leprosy

From: World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis

Study Study Design Country Follow Up (years) N Age (Years) Diagnosis Control Used Evaluated Outcome
Balagon 2011 [28] Cohort Philippines 2 589 6–73 NR MDT 2y Type II reaction
Bathki, 1992 [29] RCT India 2 16 NR Clinical and smear MDT + vaccine BI
Fajardo, 2009 [30] RCT Philippines 12 1483 15–64 Clinical and smear -MDT 1y
- 1 month of daily RFP + ofloxacin
-MDT 1y + 1-month daily RFP/ofloxacin
-Relapse
-Skin smear
Fernandes Pena 2012 [31] RCT Brazil 4.9 613 Mean 40.15 NR Monthly RFP, dapsone and clofazimine daily × 6 m Type I or II or pure neuritis
Gunawan, 2018 [32] RCT Indonesia 0.25 14 41. 71±12.53 BI and smear clarithromycin+ dapsone+ clofazimine BI
Jadhav, 1992 [33] RCT India 2 88 Mean 24 Smear RFP daily for 9 months and then 1 month till the end of 2 years + dapsone + clofazimine daily -BI
-Morphological index
Maghanoy, 2018 [34] RCT Philippines 2 100 Median 30 NR MDT + 12 months of clofazimine Type II reaction
Oliveira Penna. 2017 [35] RCT Brazil 5 613 Mean 40.2 NR RFP + dapsone + clofazimine × 6 m -BI
-Type I and II reactions
-Disability
-Relapse rate
Rao 2009 [27] Not randomized India 2 32 NR Clinical RFP + dapsone + clofazimine × 6 m Clinical and histopathological score
Sampoonachot, 1997 [36] RCT Thailand 6 60 12–75 NR -MDT + ofloxacin.
- ofloxacin + clofazimine, then MDT
-BI
-Histological improvement
Shaw, 2003 [37] Not randomized India 2 44 37.2 ± 14.3 NR RFP + clofazimine+ acedapsone + dapsone BI
Souza Cunha 2012 [38] RCT Brazil 7 after the end of tx 198 NR Untreated MB with BI  2 -MDT 1y + 1 m of ofloxacin
-MDT 1y + 1 m of daily ofloxacin
-MDT 1y + daily RFP
Relapse
Tejasvi, 2006 [39] RCT India 1 30 27.67 ± 13.08 31.50 ± 17.03 NR RFP+ sparfloxacin + clarithromycin + minocycline -BI
-Morphological index
-Histopathology
-Clinical evaluation
Villahermosa, 2004 [40] RCT Philippines 2. Additional 8y 21 16–59 Clinical and smear (>  1 of 6 smear sites having a BI  1) ROM (24 consecutive monthly observed doses of rifampin (600 mg), ofloxacin (400 mg), and minocycline (100 mg). Lesion resolution
  1. Abbreviations.- BI Bacilar index, MB Multibacilar; MDT Multidrug Treatment, NR Not reported, RFP Rifampin, ROM Rifampin-ofloxacin-minocycline Tx Treatment; RCT Randomized Controlled Trial